National Cancer Institute head named acting FDA commissioner
FDA Commissioner Scott Gottlieb said last Tuesday that he’s planning to resign in a few weeks.
Legal/Regulatory
What’s next for FDA? Four areas where the agency will have to fill a Gottlieb-sized void
What’s waiting on the desk of the next FDA commissioner.
Reports: Purdue weighs Chapter 11
The drugmaker is facing thousands of lawsuits saying the company contributed to the opioid crisis.
Democratic senator: Constituents want bipartisanship, healthcare transparency
Sen. Christopher Coons (D-DE) talked healthcare priorities at the Coalition for Healthcare Communication post-election conference in Washington D.C. on Monday.
FDA guidelines for payer, off-label communications: OK as long as ‘truthful’
Two FDA guidance documents aim to help pharma companies show the value of their drugs to payers beyond what’s included in FDA labeling.
Cannabis gets the iPhone treatment
Thanks to legalization, a new breed of startups are changing the nature of cannabis advertising.
Understanding FDA’s Blueprint for Transparency
The Food and Drug Administration regulates more than a third of the U.S. economy. And its new commissioner, Scott Gottlieb, is trying to shake up how it does so.
Five things for pharma marketers to know: Tuesday, January 23, 2018
FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW
Sandoz lines up potential third-to-market Humira copy
Although if approved, it’s not likely to launch in the U.S. for quite some time.
NORML balances federal, local action after Cole memo reversal
Once Attorney General Jeff Sessions reversed the Cole memo, NORML began applying pressure both locally and nationally for changes in marijuana laws.
